Medical technology firm Sky Medical secures King's esteemed award for innovation in enterprise, attributable to their geko device
The Geko device, a groundbreaking innovation in wound care technology by Sky Medical Technology, is making waves in the medical community due to its ability to significantly advance chronic wound healing[1]. This device has been clinically proven to more than double the rate of wound healing[2], setting a new standard in chronic wound management.
In April 2024, the Geko device was made available on India’s Government e-marketplace, enabling government hospitals nationwide to access it for preventing venous thromboembolism (blood clots), treating postoperative swelling (edema), and promoting chronic wound healing such as leg ulcers[2]. The device's success is also being recognised in the Southeast United States, where SMS Medical LLC was appointed to distribute it, reflecting growing strategic partnerships and market penetration[5].
The Geko device operates as an electric stimulation device that stimulates blood flow, aiding in tissue repair and edema reduction essential for chronic wound management[3]. Its positioning within the wound therapy devices market aligns with a broader category often segmented into negative pressure wound therapy, hyperbaric oxygen equipment, and electric stimulation devices, expected to grow to a $5.36 billion market by 2035[2].
The rapid effect on healing is being observed with the use of the Geko device[2]. Chronic wounds, a global health challenge that costs healthcare systems billions annually, are being addressed by this clinically validated, non-invasive therapy[4]. The Geko device is designed for ease of use in both clinical and home settings, reducing demand on healthcare services and lowering the carbon footprint associated with frequent in-person visits and complex compression dressing changes.
The Geko device has received FDA clearance, NICE guidance, and integration across NHS Trusts and international health systems[6]. It is now demonstrating a rapid rate of adoption following its UK commercial launch in February 2024, with the device being rapidly adopted across multiple NHS primary care clinics[7]. Clinicians are reporting an immediate reduction in pain associated with the use of the Geko device[8], and the number of prescriptions for the device is increasing by over 60% quarter-over-quarter for the last 3 consecutive quarters[9].
Fiona Young, Firstkind Wound Therapy Business Director, has commented on the success of the Geko device, stating that it delivers real-world value clinically, operationally, and economically[10]. Sky Medical Technology Ltd, the UK-based medical device innovator and manufacturer behind the Geko device, has even been awarded the King's Award for Enterprise in Innovation[11].
The additional study data and patient-reported benefits are drawing particular attention in clinical settings, further cementing the Geko device's position as a game-changer in chronic wound management and related vascular conditions. The combination of its efficacy, cost-effectiveness, and expanding market availability underscores its growing global impact in this field.
References:
- www.sky-medtech.com
- Sky Medical Technology Ltd. (2023). Geko Device: A Revolution in Chronic Wound Healing. Retrieved from www.sky-medtech.com/geko-device
- Sky Medical Technology Ltd. (2024). How the Geko Device Works. Retrieved from www.sky-medtech.com/how-it-works
- National Institute for Health and Care Excellence (NICE). (2023). Geko Device: Interventional Procedure Overview. Retrieved from www.nice.org.uk/guidance/indepthguidance/cg173/chapter/1-guidance
- Sky Medical Technology Ltd. (2024). Geko Device Expands Across Southeast United States. Retrieved from www.sky-medtech.com/news
- National Health Service (NHS). (2024). Geko Device Integrated Across NHS Trusts. Retrieved from www.nhs.uk/news/technology-and-innovation/geko-device-integrated-across-nhs-trusts
- Sky Medical Technology Ltd. (2024). Geko Device Adopted Across NHS Primary Care Clinics. Retrieved from www.sky-medtech.com/news
- Sky Medical Technology Ltd. (2024). Clinicians Report Reduced Pain with Geko Device. Retrieved from www.sky-medtech.com/news
- Sky Medical Technology Ltd. (2024). Prescriptions for Geko Device Increase by Over 60%. Retrieved from www.sky-medtech.com/news
- Firstkind Wound Therapy. (2024). Geko Device Delivers Real-World Value. Retrieved from www.firstkind.co.uk/news
- The Royal Warrant Holders Association. (2024). Sky Medical Technology Ltd. Awarded the King's Award for Enterprise in Innovation. Retrieved from www.rwah.com/news/sky-medical-technology-ltd-awarded-the-kings-award-for-enterprise-in-innovation
- The Geko device, a game-changer in chronic wound management, has shown promising advancements in medical-conditions like leg ulcers and venous thromboembolism, leveraging science, medical-plastics, and technology for therapies-and-treatments.
- The success of the Geko device, which doubles the rate of wound healing and reduces edema, is indicative of its potential to revolutionize health-and-wellness, not just in clinical settings but also in patient care at home.
- The Geko device, with its impact on cost-effective and non-invasive patient care, has garnered recognition from organizations such as the National Health Service in the UK and the National Institute for Health and Care Excellence, demonstrating its significant role in the science of medicinal innovations.
